JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

  NCT03513549

  Condition:   Agitation,Psychomotor
  Intervention:   Drug: Loxapine 10 MG
  Sponsors:   Galen Limited;   Pharmaceutical Research Associates
  Recruiting
• Optimizing Overactive Bladder Treatment

  NCT03904407

  Condition:   Overactive Bladder
  Interventions:   Other: Lactobacillus Probiotic Capsule;   Other: Matching Lactobacillus Probiotic Placebo Capsule
  Sponsors:   University of North Carolina, Chapel Hill;   Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction
  Recruiting
• Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer

  NCT03867045

  Condition:   Metastatic Renal Cell Carcinoma Treated With Cabozantinib
  Intervention:   Device: Usability of an electronic symptom management application
  Sponsors:   Duke University;   Exelixis
  Recruiting
• Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use

  NCT02870218

  Conditions:   Nicotine Addiction;   Cigarette Smoking
  Interventions:   Drug: Smoking research cigarettes with e-cigarette;   Drug: Nicotine discrimination thresholds
  Sponsors:   Rose Research Center, LLC;   National Institutes of Health (NIH);   Food and Drug Administration (FDA);   National Institute on Drug Abuse (NIDA)
  Recruiting
• Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina

  NCT03253211

  Condition:   Sickle Cell Disease
  Intervention:  
  Sponsors:   Duke University;   Agency for Healthcare Research and Quality (AHRQ)
  Recruiting
• A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)

  NCT03875651

  Conditions:   Atherosclerosis;   Heart Diseases, Coronary;   Coronary Artery Disease;   Cardiovascular Diseases
  Intervention:   Device: SYNERGY 4.50 mm and 5.0 mm Coronary Stent System
  Sponsor:   Boston Scientific Corporation
  Recruiting
• Implementation Program to Improve CHG Bathing Compliance

  NCT03898115

  Condition:   Central Line-associated Bloodstream Infection (CLABSI)
  Intervention:   Behavioral: CHG Education
  Sponsor:   Duke University
  Recruiting
• A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®

  NCT03551873

  Condition:   Chronic Idiopathic Constipation
  Intervention:   Drug: Plecanatide
  Sponsor:   Bausch Health Americas, Inc.
  Recruiting
• Placebo Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

  NCT04040816

  Conditions:   Gout;   Hyperuricemia
  Intervention:   Drug: SAP-001
  Sponsor:   Shanton Pharma Co., Ltd.
  Recruiting
• Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients

  NCT03944707

  Condition:   Asthma
  Intervention:   Drug: LOU064 or placebo treatment
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC

  NCT03077243

  Conditions:   Carcinoma, Squamous Cell;   Head and Neck Neoplasms;   Oropharyngeal Neoplasms
  Interventions:   Radiation: Intensity Modulated Radiotherapy (IMRT) - deintensified;   Radiation: Intensity Modulated Radiotherapy (IMRT) - standard;   Drug: Cisplatin (or alternative) - deintensified;   Drug: Cisplatin (or alternative) - standard;   Procedure: Assessment for surgical evaluation
  Sponsor:   UNC Lineberger Comprehensive Cancer Center
  Recruiting
• Environmental Polymorphisms Registry

  NCT00341237

  Conditions:   Diabetes;   Heart Disease;   Asthma
  Intervention:  
  Sponsor:   National Institute of Environmental Health Sciences (NIEHS)
  Recruiting
• Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

  NCT02852239

  Condition:   Renal Impairment
  Intervention:   Drug: dabrafenib
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

  NCT03281954

  Condition:   Triple Negative Breast Cancer
  Interventions:   Drug: Placebo;   Drug: Atezolizumab
  Sponsors:   NSABP Foundation Inc;   Genentech, Inc.;   Hoffmann-La Roche
  Recruiting
• Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

  NCT02993406

  Conditions:   Cardiovascular Diseases;   Statin Adverse Reaction
  Interventions:   Drug: Bempedoic acid 180 mg tablet;   Drug: Matching placebo tablet
  Sponsors:   Esperion Therapeutics;   The Cleveland Clinic
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer

  NCT02364557

  Conditions:   Dyspnea;   Fatigue;   Nausea and Vomiting;   Pain;   Stage IV Breast Cancer
  Interventions:   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

  NCT04003389

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

  NCT04003155

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

  NCT03922711

  Condition:   Parkinson Disease
  Interventions:   Drug: Pridopidine;   Drug: Placebo
  Sponsor:   Prilenia
  Recruiting
• To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

  NCT03777059

  Condition:   Episodic Migraine
  Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo;   Drug: Atogepant 10 mg
  Sponsor:   Allergan
  Recruiting
• A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

  NCT03776175

  Condition:   Non-Alcoholic Fatty Liver Disease (NAFLD)
  Interventions:   Drug: PF-05221304 Monotherapy;   Drug: PF-06865571 Monotherapy;   Drug: Placebo;   Drug: PF-05221304 and PF-06865571 Combination
  Sponsor:   Pfizer
  Recruiting
• A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

  NCT03561090

  Condition:   Gastroesophageal Reflux Disease (GERD)
  Interventions:   Drug: IW-3718;   Drug: placebo
  Sponsor:   Ironwood Pharmaceuticals, Inc.
  Recruiting
• The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

  NCT03551496

  Condition:   Critical Limb Ischemia
  Interventions:   Combination Product: Drug Eluting Stent - Below the Knee;   Device: Standard PTA Control Arm
  Sponsor:   Boston Scientific Corporation
  Recruiting
• Hemodynamic-GUIDEd Management of Heart Failure

  NCT03387813

  Conditions:   Heart Failure;   Heart Failure, Systolic;   Heart Failure, Diastolic;   Heart Failure NYHA Class II;   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV;   Heart Failure，Congestive;   Heart Failure With Reduced Ejection Fraction;   Heart Failure With Normal Ejection Fraction;   Heart Failure; With Decompensation
  Intervention:   Device: CardioMEMS™ HF System
  Sponsor:   Abbott Medical Devices
  Recruiting
• Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency

  NCT03037931

  Conditions:   Heart Failure;   Iron-deficiency
  Interventions:   Drug: Ferric carboxymaltose;   Drug: Placebos
  Sponsors:   American Regent, Inc.;   Duke Clinical Research Institute
  Recruiting
• Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)

  NCT02923193

  Condition:   Peripheral Arterial Disease
  Interventions:   Device: Shockwave Lithoplasty® Peripheral Lithoplasty System;   Drug: Medtronic IN.PACT (DCB)
  Sponsor:   Shockwave Medical, Inc.
  Recruiting
• Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

  NCT02877134

  Condition:   Crohn Disease
  Interventions:   Drug: JNJ-64304500;   Drug: Placebo;   Drug: Ustekinumab
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

  NCT03290508

  Condition:   Prostate Cancer
  Intervention:   Diagnostic Test: Prolaris Testing
  Sponsor:   Myriad Genetic Laboratories, Inc.
  Recruiting
• Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis

  NCT03042104

  Conditions:   Aortic Stenosis;   Heart Diseases
  Intervention:   Device: Edwards SAPIEN 3 THV
  Sponsor:   Edwards Lifesciences
  Recruiting
• Reducing Lung CongestIon Symptoms in Advanced Heart Failure

  NCT03499236

  Condition:   Heart Failure
  Interventions:   Device: V-Wave Interatrial Shunt;   Other: Control
  Sponsor:   V-Wave Ltd
  Recruiting
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

  NCT03664752

  Condition:   Acne Vulgaris
  Interventions:   Drug: IDP-120 Gel;   Drug: IDP-120 Vehicle Gel
  Sponsor:   Bausch Health Americas, Inc.
  Recruiting
• Comparative Effectiveness Study Telerehab Versus Conventional

  NCT03468868

  Condition:   Multiple Sclerosis
  Intervention:   Behavioral: Exercise program for people with MS
  Sponsors:   Shepherd Center, Atlanta GA;   University of Alabama at Birmingham;   University of North Carolina, Chapel Hill;   University of Georgia;   The Cleveland Clinic;   University of Colorado, Denver;   Marquette University;   Accelerated Cure Project for Multiple Sclerosis;   Patient-Centered Outcomes Research Institute
  Recruiting
• A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

  NCT04015102

  Condition:   Prostate Cancer
  Intervention:  
  Sponsors:   Myriad Genetic Laboratories, Inc.;   Carolina Urologic Research Center
  Recruiting
• A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

  NCT03803202

  Conditions:   Healthy Volunteers;   Pneumococcal Disease
  Interventions:   Biological: ASP3772;   Biological: PCV13;   Biological: PPSV23
  Sponsors:   Astellas Pharma Global Development, Inc.;   Affinivax
  Recruiting
• MT10109L in the Treatment of Glabellar Lines

  NCT03795922

  Condition:   Glabellar Lines
  Interventions:   Drug: MT10109L;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

  NCT03732833

  Condition:   Lateral Canthal Lines, Glabellar Lines
  Interventions:   Drug: MT10109L;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

  NCT04055090

  Conditions:   Painful Diabetic Neuropathy;   Diabetic Neuropathy, Painful
  Interventions:   Genetic: Long-Term Follow-Up of Patients who Received VM202;   Drug: Long-Term Follow-Up of Patients who Received Placebo
  Sponsor:   Helixmith Co., Ltd.
  Recruiting
• Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

  NCT04028492

  Conditions:   Idiopathic Gastroparesis;   Diabetic Gastroparesis;   Gastroparesis
  Interventions:   Drug: Tradipitant;   Drug: Placebo
  Sponsor:   Vanda Pharmaceuticals
  Recruiting
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

  NCT03980730

  Condition:   Alzheimer Disease
  Interventions:   Drug: Azeliragon;   Drug: Placebo
  Sponsor:   vTv Therapeutics
  Recruiting
• A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia

  NCT03965091

  Condition:   Fibromyalgia
  Interventions:   Drug: Fremanezumab - Dose A;   Drug: Fremanezumab - Dose B;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Recruiting
• Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

  NCT02720744

  Conditions:   Excessive Daytime Sleepiness;   Cataplexy;   Narcolepsy
  Interventions:   Drug: Sodium Oxybate;   Drug: Placebo
  Sponsor:   Avadel
  Recruiting
• A Study of Suboptimally Controlled Participants Previously Taking Oral Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)

  NCT03933202

  Condition:   Multiple Sclerosis
  Intervention:   Drug: Cladribine Tablets
  Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
  Recruiting
• A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

  NCT03931785

  Condition:   Irritable Bowel Syndrome With Diarrhea (IBS-D)
  Interventions:   Drug: MD-7246;   Drug: Placebo
  Sponsors:   Ironwood Pharmaceuticals, Inc.;   Allergan Sales, LLC
  Recruiting
• Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

  NCT03918629

  Condition:   Clostridium Difficile Associated Disease
  Interventions:   Biological: Clostridium difficile;   Biological: Placebo
  Sponsor:   Pfizer
  Recruiting
• Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

  NCT03902080

  Condition:   Overactive Bladder
  Interventions:   Drug: Vibegron;   Drug: Placebo
  Sponsor:   Urovant Sciences GmbH
  Recruiting
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

  NCT03901482

  Conditions:   Migraine;   Migraine With Aura;   Migraine Without Aura
  Interventions:   Drug: Dihydroergotamine;   Drug: Placebos
  Sponsor:   Satsuma Pharmaceuticals, Inc.
  Recruiting
• A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

  NCT03899259

  Condition:   Alopecia Areata
  Interventions:   Drug: Baricitinib;   Drug: Placebo
  Sponsors:   Eli Lilly and Company;   Incyte Corporation
  Recruiting
• An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

  NCT03896295

  Condition:   Generalized Myasthenia Gravis
  Intervention:   Drug: M281
  Sponsor:   Momenta Pharmaceuticals, Inc.
  Recruiting
• Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

  NCT03855137

  Condition:   Chronic Migraine
  Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445

  Condition:   Previously Treated Non-Small Cell Lung Cancer
  Intervention:   Drug: Screening Platform
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

  NCT03850483

  Condition:   Psoriasis
  Interventions:   Drug: PF-06700841;   Drug: Vehicle (Placebo)
  Sponsor:   Pfizer
  Recruiting
• Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

  NCT03841331

  Condition:   Pruritus
  Interventions:   Drug: 5 mg Serlopitant Tablets;   Drug: Matching Placebo Tablets
  Sponsor:   Menlo Therapeutics Inc.
  Recruiting
• XIENCE 28 USA Study

  NCT03815175

  Conditions:   Bleeding Disorder;   Ischemic Stroke;   Hemorrhagic Stroke;   Hematological Diseases;   Thrombocytopenia;   Coagulation Disorder;   Anemia;   Renal Insufficiency;   Coronary Artery Disease
  Interventions:   Device: XIENCE;   Drug: DAPT (aspirin and/or P2Y12 receptor inhibitor)
  Sponsor:   Abbott Medical Devices
  Recruiting
• A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

  NCT03781167

  Condition:   Parkinson's Disease (PD)
  Intervention:   Drug: ABBV-951
  Sponsor:   AbbVie
  Recruiting
• A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

  NCT03772587

  Condition:   Generalized Myasthenia Gravis
  Interventions:   Drug: M281;   Other: Placebo
  Sponsor:   Momenta Pharmaceuticals, Inc.
  Recruiting
• Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

  NCT03759392

  Condition:   Heart Failure With Reduced Ejection Fraction
  Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
  Sponsors:   Amgen;   Cytokinetics;   Servier
  Recruiting
• A Study to Assess Efficacy and Safety of SER‑287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

  NCT03759041

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Vancomycin Pre-Treatment;   Drug: Placebo for Vancomycin Pre-Treatment;   Drug: SER-287;   Drug: Placebo for SER-287
  Sponsor:   Seres Therapeutics, Inc.
  Recruiting
• A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

  NCT03713957

  Condition:   Parkinson Disease
  Interventions:   Drug: GRF6021;   Other: Placebo
  Sponsors:   Alkahest, Inc.;   Michael J. Fox Foundation for Parkinson's Research
  Recruiting
• Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep

  NCT03679884

  Condition:   Insomnia Disorder
  Interventions:   Drug: ACT-541468 10 mg;   Drug: ACT-541468 25 mg;   Drug: ACT-541468 50 mg;   Drug: Placebo
  Sponsor:   Idorsia Pharmaceuticals Ltd.
  Recruiting
• Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

  NCT03654313

  Conditions:   Atherosclerosis;   Cardiovascular Disease
  Interventions:   Biological: MEDI6570;   Biological: Placebo;   Biological: Part B Placebo
  Sponsor:   MedImmune LLC
  Recruiting
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114

  Condition:   Relapsing Multiple Sclerosis
  Interventions:   Biological: Ofatumumab;   Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);   Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);   Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);   Biological: Seasonal Quadrivalent influenza vaccine;   Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects

  NCT03618095

  Condition:   Aortic Valve Stenosis
  Intervention:   Device: LOTUS Edge Valve System
  Sponsor:   Boston Scientific Corporation
  Recruiting
• Safety and Efficacy of KPI-121 in Subjects With DED

  NCT03616899

  Condition:   Kerato Conjunctivitis Sicca
  Interventions:   Drug: KPI-121 Ophthalmic Suspension;   Drug: Vehicle
  Sponsor:   Kala Pharmaceuticals, Inc.
  Recruiting
• Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

  NCT03587805

  Condition:   Atopic Dermatitis
  Intervention:   Drug: Tralokinumab
  Sponsor:   LEO Pharma
  Recruiting
• PSD502 in Subjects With Premature Ejaculation

  NCT03578783

  Condition:   Premature Ejaculation
  Interventions:   Drug: Placebo;   Drug: PSD502
  Sponsor:   Plethora Solutions Ltd
  Recruiting
• Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep

  NCT03575104

  Condition:   Insomnia Disorder
  Interventions:   Drug: ACT-541468;   Other: Placebo
  Sponsor:   Idorsia Pharmaceuticals Ltd.
  Recruiting
• A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

  NCT03573297

  Conditions:   Bipolar I Disorder;   Mania;   Depression
  Interventions:   Drug: Cariprazine;   Drug: Placebo
  Sponsor:   Forest Laboratories
  Recruiting
• A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

  NCT03548584

  Conditions:   Agitaton Associated With Alzheimer's Dementia;   Alzheimer Dementia
  Interventions:   Drug: Brexpiprazole;   Other: Placebo
  Sponsors:   Otsuka Pharmaceutical Development & Commercialization, Inc.;   H. Lundbeck A/S
  Recruiting
• A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

  NCT03544229

  Conditions:   Diabetic Gastroparesis;   Idiopathic Gastroparesis
  Interventions:   Drug: TAK-906 Maleate;   Drug: TAK-906 Maleate Placebo
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Recruiting
• A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

  NCT03538691

  Condition:   Major Depressive Disorder
  Interventions:   Drug: Brexpiprazole;   Drug: Placebo;   Drug: Citalopram Hydrobromide;   Drug: Escitalopram;   Drug: Fluoxetine;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Duloxetine;   Drug: Venlafaxine Extended Release Oral Capsule
  Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
  Recruiting
• A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

  NCT03533114

  Condition:   Idiopathic Hypersomnia
  Interventions:   Drug: JZP-258;   Drug: Placebo Oral Solution
  Sponsor:   Jazz Pharmaceuticals
  Recruiting
• Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

  NCT03521934

  Condition:   Heart Failure-Type 2 Diabetes Mellitus
  Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
  Sponsor:   Sanofi
  Recruiting
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

  NCT03518034

  Conditions:   Hypogonadism;   Cardiovascular Diseases
  Interventions:   Drug: Testosterone;   Drug: Placebo
  Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
  Recruiting
• ECG Belt for CRT Response

  NCT03504020

  Condition:   Heart Failure
  Intervention:   Device: ECG Belt Research System
  Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
  Recruiting
• To Assess the Patients' Ability to Self-Administer Fasinumab

  NCT03491904

  Conditions:   Osteoarthritis, Knee;   Osteoarthritis, Hip
  Interventions:   Drug: Fasinumab AI;   Drug: Fasinumab PFS
  Sponsors:   Regeneron Pharmaceuticals;   Teva Pharmaceutical Industries, Ltd.
  Recruiting
• FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

  NCT03490201

  Condition:   Ventricular Tachycardia
  Interventions:   Device: Market Approved RF Ablation System;   Device: FlexAbility SE Ablation Catheter
  Sponsor:   Abbott Medical Devices
  Recruiting
• Benefits of µCor in Ambulatory Decompensated Heart Failure

  NCT03476187

  Condition:   Heart Failure
  Intervention:   Device: µCor
  Sponsor:   Zoll Medical Corporation
  Recruiting
• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223

  Condition:   Acute Coronary Syndrome
  Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
  Sponsor:   CSL Behring
  Recruiting
• Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies

  NCT03467152

  Condition:   Dementia With Lewy Bodies
  Interventions:   Drug: E2027;   Drug: Placebo
  Sponsor:   Eisai Inc.
  Recruiting
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

  NCT03464136

  Condition:   Crohn Disease
  Interventions:   Biological: Placebo for Ustekinumab;   Biological: Placebo for Adalimumab;   Biological: Ustekinumab (6 mg/kg);   Biological: Ustekinumab (90 mg);   Biological: Adalimumab (40 mg)
  Sponsor:   Janssen Scientific Affairs, LLC
  Recruiting
• Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

  NCT03444870

  Condition:   Alzheimer Disease
  Interventions:   Drug: Gantenerumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

  NCT03443973

  Condition:   Alzheimer's Disease
  Interventions:   Drug: Gantenerumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

  NCT03345849

  Condition:   Crohn's Disease
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

  NCT03345836

  Condition:   Crohn's Disease
  Interventions:   Other: Matching placebo for upadacitinib;   Drug: upadacitinib
  Sponsor:   AbbVie
  Recruiting
• Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

  NCT03334851

  Conditions:   Systemic Lupus Erythematosus;   Rheumatoid Arthritis
  Interventions:   Drug: PF-06835375;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence

  NCT03320850

  Conditions:   Urinary Incontinence;   Overactive Bladder With Urinary Incontinence
  Interventions:   Drug: OnabotulinumtoxinA and Hydrogel admixture;   Drug: Placebo and Hydrogel admixture
  Sponsor:   Allergan
  Recruiting
• Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)

  NCT03257436

  Condition:   Left Ventricular Dysfunction
  Intervention:   Device: CRT-D
  Sponsors:   Boston Scientific Corporation;   ICON Clinical Research
  Recruiting
• An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus

  NCT03252587

  Condition:   Systemic Lupus Erythematosus
  Interventions:   Drug: BMS-986165;   Other: Placebo
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• Electronic Patient Reporting of Symptoms During Cancer Treatment

  NCT03249090

  Conditions:   Advanced Cancer;   Metastatic Cancer
  Interventions:   Other: Patient Self-Reporting of Symptoms;   Other: Usual Care Delivery
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   University of North Carolina;   Mayo Clinic;   American Society of Clinical Oncology;   American Cancer Society, Inc.;   Dana-Farber Cancer Institute
  Recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711

  Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
  Interventions:   Biological: Nivolumab;   Other: Patient Observation
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

  NCT03183128

  Condition:   Clostridium Difficile Infection
  Interventions:   Drug: SER-109;   Drug: Placebo
  Sponsor:   Seres Therapeutics, Inc.
  Recruiting
• Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

  NCT03175744

  Condition:   Critical Limb Ischemia
  Interventions:   Device: Stellarex DCB;   Device: PTA Catheter
  Sponsor:   Spectranetics Corporation
  Recruiting
• An Effectiveness-Implementation Trial of SPIRIT in ESRD

  NCT03138564

  Condition:   End Stage Renal Disease
  Interventions:   Behavioral: SPIRIT;   Behavioral: Comparison Condition
  Sponsors:   Emory University;   National Institute of Nursing Research (NINR)
  Recruiting
• A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

  NCT03138499

  Condition:   Hodgkin's Disease
  Interventions:   Biological: Nivolumab;   Biological: Brentuximab vedotin
  Sponsors:   Bristol-Myers Squibb;   Seattle Genetics, Inc.;   Ono Pharmaceutical Co. Ltd
  Recruiting
• Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization

  NCT03127722

  Condition:   Contraception
  Interventions:   Procedure: Blood draw;   Device: ESSURE (BAY1454032);   Procedure: Laparoscopic tubal sterilization
  Sponsor:   Bayer
  Recruiting
• Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

  NCT03108456

  Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
  Interventions:   Device: Orbital Atherectomy;   Device: Balloon
  Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
  Recruiting
• A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989

  NCT03105102

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab SC;   Drug: risankizumab IV;   Drug: placebo for risankizumab IV;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

  NCT03077412

  Condition:   Fistulizing Crohn's Disease
  Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
  Sponsors:   Gilead Sciences;   Galapagos NV
  Recruiting
• MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

  NCT03072927

  Condition:   Lumbar Spinal Stenosis
  Intervention:   Device: MILD
  Sponsor:   Vertos Medical, Inc.
  Recruiting
• Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

  NCT03070899

  Conditions:   Uterine Fibroids;   Heavy Menstrual Bleeding
  Interventions:   Drug: Placebo + Placebo Add-back;   Drug: OBE2109 + Placebo Add-back;   Drug: OBE2109 + Add-back
  Sponsor:   ObsEva SA
  Recruiting
• Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection

  NCT03061305

  Conditions:   Cancer;   Adult Solid Tumor;   Lymphoma
  Intervention:  
  Sponsor:   Strata Oncology
  Recruiting
• Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

  NCT03046056

  Condition:   Small Bowel Crohn's Disease
  Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
  Sponsors:   Gilead Sciences;   Galapagos NV
  Recruiting
• AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH

  NCT03028740

  Condition:   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Cenicriviroc;   Drug: Placebo
  Sponsor:   Tobira Therapeutics, Inc.
  Recruiting
• QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

  NCT03022825

  Condition:   Bladder Cancer
  Interventions:   Drug: ALT-803;   Drug: BCG
  Sponsor:   Altor BioScience
  Recruiting
• Myocardial Ischemia and Transfusion

  NCT02981407

  Conditions:   Myocardial Infarction;   Anemia
  Intervention:   Biological: Red Blood Cell Transfusion
  Sponsors:   Rutgers, The State University of New Jersey;   University of Pittsburgh;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

  NCT02926911

  Conditions:   DCIS;   Ductal Carcinoma in Situ
  Interventions:   Other: Guideline Concordant Care;   Other: Active Surveillance
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   Duke University;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   New York University;   Washington University School of Medicine
  Recruiting
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

  NCT02914561

  Condition:   Crohn's Disease
  Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
  Sponsors:   Gilead Sciences;   Galapagos NV
  Recruiting
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

  NCT02876835

  Condition:   Anaemia
  Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
  Sponsor:   GlaxoSmithKline
  Recruiting
• RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers

  NCT02818972

  Condition:   Aortic Aneurysm, Thoracic
  Intervention:   Device: RelayPro
  Sponsor:   Bolton Medical
  Recruiting
• Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

  NCT02793583

  Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
  Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
  Sponsor:   TG Therapeutics, Inc.
  Recruiting
• The PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

  NCT02675114

  Condition:   Aortic Stenosis
  Interventions:   Procedure: Surgical aortic valve replacement (SAVR);   Device: Transcatheter Aortic Valve Replacement (TAVR)
  Sponsor:   Edwards Lifesciences
  Recruiting
• Baroreflex Activation Therapy for Heart Failure

  NCT02627196

  Condition:   Heart Failure
  Interventions:   Device: BAROSTIM NEO® System;   Drug: Medical Management
  Sponsor:   CVRx, Inc.
  Recruiting
• An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

  NCT02542696

  Condition:   Parkinson Disease
  Intervention:   Drug: APL-130277
  Sponsor:   Sunovion
  Recruiting
• Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02520778

  Conditions:   Advanced Lung Non-Squamous Non-Small Cell Carcinoma;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   EGFR NP_005219.2:p.T790M;   Metastatic Lung Non-Squamous Non-Small Cell Carcinoma;   Stage III Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIB Lung Non-Small Cell Cancer AJCC v7;   Stage IV Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Drug: Navitoclax;   Drug: Osimertinib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02502266

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

  NCT02489539

  Condition:   Aortic Aneurysm, Abdominal
  Intervention:   Device: GORE® EXCLUDER® Conformable AAA Endoprosthesis
  Sponsor:   W.L.Gore & Associates
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

  NCT02329327

  Condition:   Bleeding
  Intervention:   Biological: Andexanet
  Sponsors:   Portola Pharmaceuticals;   Population Health Research Institute
  Recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217

  Condition:   Carotid Stenosis
  Interventions:   Procedure: Carotid endarterectomy (CEA);   Device: Carotid Stenting (CAS);   Other: Intensive Medical Management - no CEA;   Other: Intensive Medical Management - no CAS
  Sponsors:   Thomas G. Brott, M.D.;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia

  NCT02060630

  Condition:   Critical Limb Ischemia
  Interventions:   Procedure: Open surgical revascularization;   Device: Endovascular revascularization
  Sponsors:   New England Research Institutes;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Boston Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Dimethyl Fumarate (DMF) Observational Study

  NCT02047097

  Condition:   Multiple Sclerosis
  Intervention:   Drug: dimethyl fumarate
  Sponsor:   Biogen
  Recruiting
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

  NCT01996865

  Condition:   Lymphoma, Non-Hodgkin
  Interventions:   Drug: Lenalidomide;   Drug: Rituximab
  Sponsor:   Celgene
  Recruiting
• Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

  NCT01938248

  Conditions:   Atrial Fibrillation;   Stroke
  Interventions:   Drug: Apixaban;   Drug: aspirin
  Sponsors:   Population Health Research Institute;   Bristol-Myers Squibb;   Pfizer;   Medtronic;   Canadian Institutes of Health Research (CIHR);   Hamilton Health Sciences Foundation
  Recruiting
• Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry

  NCT01729455

  Condition:   Systemic Lupus Erythematosus
  Interventions:   Biological: BENLYSTA;   Other: SLE treatment
  Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
  Recruiting
• Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853

  Condition:   Lung Cancer
  Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Psoriasis Longitudinal Assessment and Registry (PSOLAR)

  NCT00508547

  Conditions:   Psoriasis;   Arthritis, Psoriatic
  Interventions:   Biological: Ustekinumab;   Biological: Biological therapies other than infliximab, ustekinumab and guselkumab;   Drug: Conventional systemic agents;   Biological: Infliximab;   Biological: Guselkumab
  Sponsor:   Janssen Scientific Affairs, LLC
  Recruiting
• Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity

  NCT03746522

  Conditions:   Bardet Biedl Syndrome (BBS);   Alström Syndrome (AS)
  Interventions:   Drug: Setmelanotide;   Drug: Placebos
  Sponsor:   Rhythm Pharmaceuticals, Inc.
  Recruiting
• A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

  NCT03539601

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Crisaborole ointment, 2%;   Drug: Hydrocortisone butyrate cream, 0.1%;   Drug: Pimecrolimus cream, 1%;   Drug: Crisaborole Vehicle
  Sponsor:   Pfizer
  Recruiting
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

  NCT03893448

  Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
  Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

  NCT03745638

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Ruxolitinib cream;   Drug: Vehicle cream
  Sponsor:   Incyte Corporation
  Recruiting
• Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

  NCT03627767

  Conditions:   Dermatitis;   Dermatitis, Atopic;   Eczema;   Skin Diseases;   Skin Diseases, Genetic;   Genetic Diseases, Inborn;   Skin Diseases, Eczematous;   Hypersensitivity;   Hypersensitivity, Immediate;   Immune System Diseases
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• Disrupt CAD III With the Shockwave Coronary IVL System

  NCT03595176

  Conditions:   Coronary Artery Disease;   Myocardial Infarction
  Intervention:   Device: Lithotripsy
  Sponsor:   Shockwave Medical, Inc.
  Recruiting
• A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

  NCT03562156

  Condition:   Recurrent Vulvovaginal Candidiasis
  Interventions:   Drug: VT-1161;   Drug: Placebo
  Sponsor:   Mycovia Pharmaceuticals Inc.
  Recruiting
• Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer's Disease

  NCT03446001

  Condition:   Alzheimer Disease
  Interventions:   Drug: TRx0237 8 mg/day;   Drug: Placebo;   Drug: TRx0237 16 mg/day
  Sponsor:   TauRx Therapeutics Ltd
  Recruiting
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

  NCT03105128

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

  NCT03104413

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
  Sponsor:   AbbVie
  Recruiting
• Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity

  NCT03013543

  Conditions:   Pro-opiomelanocortin (POMC) Deficiency Obesity (Heterozygous or Epigenetic);   Leptin Receptor Deficiency Obesity;   Bardet-Biedl Syndrome;   Alstrom Syndrome;   Smith-Magenis Syndrome
  Intervention:   Drug: Setmelanotide
  Sponsor:   Rhythm Pharmaceuticals, Inc.
  Recruiting
• 3T MRI CIED Post-Approval Study

  NCT02969395

  Condition:   Cardiac Rhythm Disorder
  Intervention:  
  Sponsor:   Medtronic
  Recruiting
• Chronic Hypertension and Pregnancy (CHAP) Project

  NCT02299414

  Condition:   Hypertension
  Interventions:   Drug: Anti-hypertensive therapy;   Other: No anti-hypertensive therapy (unless BP is severe)
  Sponsors:   University of Alabama at Birmingham;   Columbia University;   Drexel University College of Medicine;   Rutgers, The State University of New Jersey;   Lehigh Valley Hospital;   Saint Peters University Hospital;   Christiana Care Health Services;   Washington University School of Medicine;   Duke University;   University of Texas Southwestern Medical Center;   The University of Texas Health Science Center, Houston;   Stanford University;   University of Pennsylvania;   The University of Texas Medical Branch, Galveston;   University of Utah;   Intermountain Health Care, Inc.;   University of California, San Francisco;   Johns Hopkins University;   University of Pittsburgh;   Ochsner Health System;   University of North Carolina, Chapel Hill;   National Heart, Lung, and Blood Institute (NHLBI);   WakeMed Health and Hospitals;   San Francisco General Hospital;   McKay-Dee Hospital;   Winthrop University Hospital;   New York Hospital Queens;   Latter Day Saints Hospital;   Lyndon B Johnson General Hospital;   Virtua Medical Group;   Bayview Medical Center;   Duke Regional Hospital;   Utah Valley Regional Medical Center;   Northwestern;   Brown (WIHRI);   Baylor College of Medicine;   Case Western/Metro Health;   Ohio State University;   University of Iowa;   University of California, San Diego;   Indiana University;   Unity Point Health-Meriter Hospital WI;   Weill Medical College of Cornell University;   University of Oklahoma;   Medical University of South Carolina;   Beaumont Hospital;   University of Colorado, Denver;   University of Kansas Medical Center;   Denver Health and Hospital Authority;   Gundersen Health System;   Aurora Health Care;   Oregon Health and Science University;   Medical College of Wisconsin;   Temple University;   New Jersey Medical School;   University of South Alabama;   Vanderbilt University;   University of Arkansas;   Miami Valley Hospital;   Emory University;   St. Luke's Hospital and Health Network, Pennsylvania;   Cleveland Clinic Fairview Hospital;   University of Tennessee Health Science Center;   TriHealth Inc.;   Cleveland Clinic Hillcrest Hospital;   Tulane University;   Yale University;   Arrowhead Regional Medical Center
  Recruiting
• Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement

  NCT02202434

  Condition:   Aortic Stenosis
  Interventions:   Device: Lotus Valve System;   Device: CoreValve/Evolut R Transcatheter Aortic Valve Replacement System;   Device: LOTUS Edge Valve System
  Sponsor:   Boston Scientific Corporation
  Recruiting
• Product Surveillance Registry

  NCT01524276

  Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
  Intervention:  
  Sponsor:   Medtronic
  Recruiting
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

  NCT01442194

  Condition:   Multiple Sclerosis
  Interventions:   Drug: other disease-modifying therapy;   Drug: Fingolimod
  Sponsor:   Novartis Pharmaceuticals
  Recruiting